차세대 시퀀싱 키트 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 워크플로우별, 시퀀싱 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Next Generation Sequencing Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Workflow, By Sequencing Type, By Application, By End User By Region and Competition, 2020-2030F
상품코드:1778881
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 188 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
차세대 시퀀싱 키트 세계 시장은 2024년에 82억 4,000만 달러로 평가되었고, 예측 기간 중 연평균 복합 성장률(CAGR)은 8.34%를 나타낼 전망이며, 2030년에는 132억 2,000만 달러에 이를 것으로 예측됩니다.
차세대 시퀀싱(NGS) 키트 세계 시장은 임상 진단, 학술 연구, 의약품 개발에서 유전체 기술의 활용이 확산됨에 따라 급성장하고 있습니다. NGS 키트는 복잡한 시퀀싱 워크플로우를 간소화하고 탁월한 속도와 정확도로 DNA와 RNA의 고성능 분석을 가능하게 하는 필수적인 구성 요소입니다. 이 키트는 암 유전체학, 희귀 유전질환 스크리닝, 비침습적 산전검사(NIPT), 병원체 검출 등의 분야에서 특히 유용하게 활용될 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
82억 4,000만 달러
시장 규모 : 2030년
132억 2,000만 달러
CAGR : 2025-2030년
8.34%
급성장 부문
시퀀싱 시약 키트
최대 시장
북미
시장 성장의 주요 촉진요인은 개인 맞춤형 의료에 대한 수요 증가로, NGS를 통해 환자별 유전자 변이를 식별하고 맞춤형 치료 계획을 수립할 수 있게 되었습니다는 점입니다. 이러한 개인 맞춤형 의료로의 전환은 특히 종양학에서 두드러지게 나타나고 있으며, NGS는 종양 프로파일링과 치료 반응 모니터링에 점점 더 많이 사용되고 있습니다. 예를 들어, 2023년 11월, Yourgene Health와 PacBio는 롱 리드 시퀀싱 워크플로우를 강화하기 위한 협력을 발표했습니다. PacBio는 긴 DNA 단편의 효율적인 크기 선택을 위한 Yourgene의 LightBench 장비를 승인했습니다. 이번 파트너십은 시퀀싱 프로세스를 간소화하고, 유전체 분석의 정확성을 향상시키며, 연구 및 임상 진단 분야의 첨단 용도를 지원하는 것을 목표로 하고 있습니다. 시퀀싱 비용은 최근 몇 년 동안 크게 낮아져 전 세계 중소규모의 연구소와 클리닉에 보다 친숙하게 다가갈 수 있게 되었습니다.
주요 시장 성장 촉진요인
유전자 질환과 암의 유병률 증가
주요 시장 과제
높은 초기 설정 및 운영 비용
주요 시장 동향
시퀀싱 기술의 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
워크플로우별(라이브러리 조제, 클러스터 생성, 시퀀싱 시약 키트)
시퀀싱 유형별(WES 및 WGS, 대상 시퀀싱, 롱 리드 시퀀싱, 기타 시퀀싱)
용도별(종양학, 희귀질환, 유전성 질환, 생식 의료, 기타)
최종사용자별(학술연구기관, 제약 바이오테크놀러지 기업, 임상 및 진단실험실, 기타)
지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
기업별(2024년)
시장 맵
제6장 북미의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 차세대 시퀀싱 키트 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
제13장 세계의 차세대 시퀀싱 키트 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
산업내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Bio-Rad Laboratories, Inc.
BGI Group.
Creative Biogene.
Danaher.
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Illumina, Inc.
Oxford Nanopore Technologies plc.
Pacific Biosciences of California, Inc.
PerkinElmer Inc.
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
Global Next Generation Sequencing Kits Market was valued at USD 8.24 billion in 2024 and is expected to reach USD 13.22 billion by 2030 with a CAGR of 8.34% during the forecast period. The Global Next Generation Sequencing (NGS) Kits Market continues to grow rapidly as the use of genomic technologies becomes more widespread across clinical diagnostics, academic research, and pharmaceutical development. NGS kits are essential components that streamline complex sequencing workflows, enabling high-throughput analysis of DNA and RNA with exceptional speed and accuracy. These kits are particularly vital in applications such as cancer genomics, rare genetic disorder screening, non-invasive prenatal testing (NIPT), and pathogen detection.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 8.24 Billion
Market Size 2030
USD 13.22 Billion
CAGR 2025-2030
8.34%
Fastest Growing Segment
Sequencing Reagents Kits
Largest Market
North America
A key driver of market growth is the rising demand for personalized medicine, where NGS enables the identification of patient-specific genetic mutations to guide tailored treatment plans. This shift toward individualized care is particularly evident in oncology, where NGS is increasingly used for tumor profiling and monitoring treatment response. For instace, in November 2023, Yourgene Health and PacBio announced a collaboration to enhance long-read sequencing workflows. PacBio approved Yourgene's LightBench instrument for efficient size selection of long DNA fragments. This partnership aims to streamline sequencing processes and improve accuracy in genomic analysis, supporting advanced applications in research and clinical diagnostics. The cost of sequencing has dropped significantly in recent years, making these technologies more accessible to small and mid-sized laboratories and clinics globally.
Key Market Drivers
Increasing Prevalence of Genetic Disorders and Cancer
The increasing prevalence of genetic disorders and cancer is a significant driver propelling the growth of the Global Next Generation Sequencing (NGS) Kits Market. Genetic disorders, including conditions such as cystic fibrosis, sickle cell anemia, and Duchenne muscular dystrophy, are affecting a growing portion of the global population. At the same time, cancer remains one of the leading causes of death worldwide, with an estimated 20 million new cancer cases diagnosed globally in 2022, according to the World Health Organization. Also, According to WHO 2025, anemia is a major global health concern, especially among young children, pregnant women, and menstruating girls and women. It disproportionately affects rural, low-income, and uneducated populations in low- and lower-middle-income countries. In 2019, anemia caused 50 million healthy life years lost, mainly due to iron deficiency, thalassaemia, sickle cell trait, and malaria. Early detection and accurate diagnosis are critical in managing these conditions, and NGS technologies are revolutionizing how clinicians identify genetic mutations and oncogenic alterations. NGS kits enable the rapid, comprehensive analysis of entire genomes or targeted gene panels, allowing researchers and healthcare professionals to detect pathogenic variants with high precision. In oncology, NGS is used extensively to perform tumor profiling, assess minimal residual disease, and guide treatment selection based on the genetic characteristics of individual tumors. This level of insight is not possible with traditional diagnostic methods. As a result, hospitals and diagnostic laboratories are increasingly incorporating NGS into routine testing protocols.
The rise in inherited genetic disorders has underscored the need for carrier screening, newborn screening, and prenatal testing-all areas where NGS kits play a central role. The growing use of non-invasive prenatal testing (NIPT) and whole-exome or whole-genome sequencing in pediatrics further amplifies demand. The public and private investments in genomics research aimed at understanding genetic diseases have boosted the deployment of NGS kits in research settings. With the global burden of cancer and genetic disorders on the rise, the demand for accurate, efficient, and cost-effective diagnostic tools will continue to accelerate, making NGS kits indispensable in both clinical and research environments.
Key Market Challenges
High Initial Setup and Operational Costs
High initial setup and operational costs represent one of the most significant challenges in the Global Next Generation Sequencing (NGS) Kits Market, particularly for smaller laboratories, research institutions, and healthcare facilities in low- and middle-income countries. While the cost of sequencing per genome has decreased over the years, the overall investment required to establish and maintain an NGS infrastructure remains substantial. This includes the purchase of high-throughput sequencing platforms, automated sample preparation systems, data analysis tools, and the NGS kits themselves, which are often costly due to their complexity and specificity. Beyond hardware and consumables, operational costs include regular maintenance, calibration, and the need for skilled personnel to manage sequencing workflows and interpret complex genomic data. In addition, storage and management of large datasets generated by NGS require robust IT infrastructure, including secure servers and advanced bioinformatics software-further adding to the total cost burden. These financial barriers can delay or even prevent the adoption of NGS technologies in many clinical and research settings, despite growing demand for advanced genomic testing in oncology, rare diseases, and infectious disease surveillance. The high cost structure also limits the ability of healthcare systems to offer NGS-based testing at scale, particularly in public health programs.
To address these challenges, market players are exploring cost-reduction strategies such as miniaturized sequencing platforms, simplified library preparation kits, and cloud-based bioinformatics solutions. The broader adoption depends on public-private partnerships, government subsidies, and expanded reimbursement frameworks that help offset upfront costs and make NGS technologies more accessible globally.
Key Market Trends
Advancements in Sequencing Technologies
Advancements in sequencing technologies are significantly shaping the future of the Global Next Generation Sequencing (NGS) Kits Market. Over the past decade, NGS has seen rapid progress in both its capabilities and accessibility, leading to a surge in applications across clinical diagnostics, research, and personalized medicine. These innovations are not only enhancing the accuracy and throughput of NGS but also reducing the cost and time required for sequencing, making it more accessible to a broader range of laboratories and healthcare providers. One of the most notable advancements is the development of single-molecule sequencing technologies. Companies like Oxford Nanopore Technologies have introduced platforms that sequence DNA directly without the need for amplification, allowing for longer reads and improved resolution of complex genomic regions. This is particularly valuable in areas like structural variation detection and de novo genome assembly, which were challenging with traditional sequencing technologies.
Another significant advancement is short-read sequencing improvements, especially by market leaders like Illumina, which have optimized their platforms for better accuracy, speed, and cost-effectiveness. These advancements are critical for large-scale projects and clinical applications, where speed and precision are essential. The introduction of long-read sequencing technologies is enabling more detailed and comprehensive genome analyses, allowing for the detection of rare mutations and previously undetectable genomic variations. The emergence of portable and miniaturized sequencing devices is also transforming the NGS market. These compact devices, such as the MinION from Oxford Nanopore, offer real-time sequencing capabilities, making genomic analysis possible in resource-limited settings and field-based applications. The integration of AI and machine learning into sequencing workflows is enhancing data analysis. These technologies are improving the ability to identify meaningful genetic variants and speed up the process of data interpretation, which is a critical factor in the clinical application of NGS technologies. These advancements are not only enhancing the capabilities of NGS kits but are also driving their broader adoption across a variety of industries, from healthcare to agriculture and environmental science, making NGS an indispensable tool for the future.
Key Market Players
Bio-Rad Laboratories, Inc.
BGI Group.
Creative Biogene
Danaher.
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Illumina, Inc.
Oxford Nanopore Technologies plc.
Pacific Biosciences of California, Inc.
PerkinElmer Inc.
Report Scope:
In this report, the Global Next Generation Sequencing Kits Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Next Generation Sequencing Kits Market, By Workflow:
Library Preparation
Cluster Generation
Sequencing Reagents Kits
Next Generation Sequencing Kits Market, By Sequencing Type:
WES and WGS
Targeted Sequencing
Long Read Sequencing
Other Sequencing
Next Generation Sequencing Kits Market, By Application:
Oncology
Rare Diseases
Genetic Disorders
Reproductive Health
Others
Next Generation Sequencing Kits Market, By End User:
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Clinical and Diagnostic Laboratories
Others
Next Generation Sequencing Kits Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.
Available Customizations:
Global Next Generation Sequencing Kits Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Next Generation Sequencing Kits Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
5.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
